Jane Street’s 4D Molecular Therapeutics FDMT Stock Holding History

Jane Street’s Portfolio FDMT Stock Details FDMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-61,900	Closed	-$576K	–	12003
2026 Q1	$576K	Buy	+61,900	New	+$539K	﹤0.01%	7716
2024 Q4	–	Sell	-59,000	Closed	-$638K	–	9732
2024 Q3	$638K	Buy	59,000 +19,400	+49%	+$322K	﹤0.01%	6759
2024 Q2	$831K	Sell	39,600 -900	-2%	-$22.6K	﹤0.01%	6126
2024 Q1	$1.29M	Buy	+40,500	New	+$1.03M	﹤0.01%	4933

Other funds holding FDMT

Jupiter Topco New York $245B AUM

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

TECP

Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Jane Street's FDMT Position: Q2 2026 in Review

Jane Street sold out of 4D Molecular Therapeutics (FDMT) in Q2 2026, closing a stake of 39,694 shares — an estimated $387K sold.

Jane Street first reported a position in FDMT in Q4 2022 and held it in 13 quarters. The position peaked at $2.8M in Q2 2024. 157 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

Jane Street reported no remaining 4D Molecular Therapeutics position as of Q2 2026 after selling out during the quarter.
Jane Street sold 39,694 4D Molecular Therapeutics shares in Q2 2026, an estimated $387K.
Jane Street first reported a position in 4D Molecular Therapeutics in Q4 2022 and held it in 13 quarters.
Jane Street's 4D Molecular Therapeutics position peaked at $2.8M in Q2 2024.
157 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.